Crispr Therapeutics AG (NASDAQ:CRSP) saw a significant drop in short interest in December. As of December 13th, there was short interest totalling 3,400,000 shares, a drop of 6.1% from the November 28th total of 3,620,000 shares. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio is presently 3.4 days. Approximately 9.9% of the shares of the stock are short sold.
Shares of CRSP traded down $0.21 during mid-day trading on Tuesday, hitting $58.12. The company’s stock had a trading volume of 1,238,732 shares, compared to its average volume of 1,144,695. Crispr Therapeutics has a 52-week low of $29.34 and a 52-week high of $74.00. The company’s 50-day moving average is $64.35 and its 200-day moving average is $52.31. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -126.35 and a beta of 3.20.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, sell-side analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 in the last quarter. 21.40% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. Nikko Asset Management Americas Inc. increased its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after acquiring an additional 906,006 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics in the third quarter valued at approximately $21,167,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in shares of Crispr Therapeutics in the second quarter valued at approximately $5,165,000. 49.83% of the stock is currently owned by institutional investors.
A number of analysts have recently weighed in on CRSP shares. ValuEngine lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 3rd. Oppenheimer lifted their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Canaccord Genuity lifted their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Finally, Roth Capital boosted their price target on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $71.38.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What sectors are represented in the FTSE 100 index?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.